Skip to main content
NewslettersWatchlist

Clene Inc(CLNN-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low0.3700
Day High0.3920
Open:0.3920
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Investor Brand Network
Clene (NASDAQ: CLNN) Announces Participation Schedule for May Conferences
Investor Brand Network
Clene (NASDAQ: CLNN) Releases Q1 2024 Financial Numbers, Operation Highlights
Investor Brand Network
Clene (NASDAQ: CLNN) Presents Findings on Phase 2 VISIONARY-MS LTE at American Academy of Neurology Annual Meeting
Investor Brand Network
Clene (NASDAQ: CLNN) Continues Development of CNM Au8(R) for Neurodegenerative Diseases
Investor Brand Network
Clene (NASDAQ: CLNN) Announces Study Results for CNM-Au8 as MS Treatment Presented at AAN Conference
Investor Brand Network
Clene (NASDAQ: CLNN) Looking to Advance Discussions for Accelerated Approval, New NDA for CNM-Au8(R)
Investor Brand Network
Clene (NASDAQ: CLNN) has Emerged as a Leader in the Neurodegenerative Field Utilizing a Novel Nanotherapeutic Drug
Investor Brand Network
Clene (NASDAQ: CLNN) Announces Publication in ACS Pharmacology & Translational Science
Investor Brand Network
Clene (NASDAQ: CLNN) Announces Operational Highlights for Lead Therapeutic Candidate for ALS and MS
Investor Brand Network
Clene’s (NASDAQ: CLNN) Work in Nanotechnology Highlighted in ‘First in Human’ Podcast
Investor Brand Network
Clene (NASDAQ: CLNN) Announces Publication of Peer-Reviewed Research for CNM-Au8(R)
Investor Brand Network
Clene (NASDAQ: CLNN) Announces FY 2023 Results, Recent Operating Highlights
Investor Brand Network
Clene (NASDAQ: CLNN) Announces Participation at 36th Annual Roth Conference
Investor Brand Network
Clene (NASDAQ: CLNN), Subsidiary Report Positive Clinical Results of CNM-Au8 Treatment
Investor Brand Network
Clene’s (NASDAQ: CLNN) CNM-Au8 Aiming to Address Neurodegenerative Diseases from New Angle
Investor Brand Network
Clene (NASDAQ: CLNN) Announces Statistically Significant Results from Independent Analyses of ALS Patient Data
Investor Brand Network
Clene (NASDAQ: CLNN) Eyes ‘Rarely Seen’ Clinically Significant Improvement in MS Patients
Investor Brand Network
Clene (NASDAQ: CLNN) Revolutionizes Approach to Restore Neuronal Health in Neurodegenerative Disease with CNM-Au8(R)
Investor Brand Network
Clene (NASDAQ: CLNN) CEO Discusses MS Trial Results During Latest Proactive Interview
Investor Brand Network
Clene (NASDAQ: CLNN) Reports Statistically Significant Long-Term Improvements for VISIONARY-MS Participants
TheNewswire.com
Clene Inc. announces positive results from CNM-Au8 results from MS trial
Investor Brand Network
Clene’s (NASDAQ: CLNN) CNM-Au8 Produces ‘Significant and Very Promising Effect’ in Parkinson’s, MS
Investor Brand Network
Clene (NASDAQ: CLNN) VISIONARY-MS Trial Data May Support CNM-Au8(R) as MS Treatment
Investor Brand Network
Clene (NASDAQ: CLNN) Announces Significant Positive Results from LTE VISIONARY-MS Trial
Investor Brand Network
Clene’s (NASDAQ: CLNN) Phase 2 REPAIR-PD and REPAIR-MD Trials Support Advancement to Phase 3
Investor Brand Network
Clene (NASDAQ: CLNN) Announces New Data from HEALEY ALS Platform Trial
Investor Brand Network
How Clene (NASDAQ: CLNN) CNM-Au8(R) Takes Advantage of Gold Nanocrystals to Target Neurodegenerative Disorders
Investor Brand Network
Clene (NASDAQ: CLNN) Lead Drug Candidate Featured in Peer-Reviewed Publication
Investor Brand Network
Clene’s (NASDAQ: CLNN) Long-Term Follow-Up Data Shows Significantly Improved Survival in ALS Patients
Investor Brand Network
Nobel Prize in Chemistry’s Spotlight on Nanotechnology Shines Light on Clene (NASDAQ: CLNN) Efforts to Develop Catalytically Active Nanoparticles
Investor Brand Network
Clene (NASDAQ: CLNN) Capitalizing on Promising Chemical and Therapeutic Properties of Nanocrystals
Investor Brand Network
Clene (NASDAQ: CLNN) Among Grant Awardees Selected to Advance Scientific Research on ALS

Profile

Clene Inc. is a clinical-stage biopharmaceutical company. It is focused on the development of unique therapeutics for neurodegenerative diseases. Clene Nanomedicine Inc., formerly known as Tottenham Acquisition I Limited, is based in SALT LAKE CITY.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.